or safety visits occur on-site, while routine assessments are done remotely. Telehealth consultations replace certain in-person follow-ups, while home nursing visits handle blood draws, vital signs, and even ECGs. For elderly participants, these models remove the travel barrier, reduce fatigue, and allow caregivers to be present more easily.

One case study in a cardiovascular outcomes trial found that introducing home visits for geriatric participants reduced visit-related discontinuations by 40%. Sampling protocols were adapted to use microsampling kits with low blood volume requirements. Assay performance remained robust, with LOD of 0.05 ng/mL and LOQ of 0.10 ng/mL maintained across home and site collections. Carryover controls ensured MACO remained ≤0.1%, meeting GMP standards.

Reducing Visit Frequency and Consolidating Assessments

One of the most effective burden-reduction strategies is to review the schedule of events and identify opportunities to combine assessments. For example, laboratory tests, cognitive assessments, and safety questionnaires can be conducted during a single home or site visit. Adaptive trial designs allow for spacing out visits if interim safety data are favorable. This approach not only reduces participant fatigue but also lowers site workload and operational costs.

When fewer visits are possible, remote monitoring fills the gap. Wearable devices, electronic patient-reported outcomes (ePRO), and home BP/ECG devices can provide continuous data between visits. Regulatory acceptance of digital endpoints has increased, provided they are validated and data integrity is assured. Validation reports should document device accuracy and calibration intervals, ensuring compliance with both FDA and EMA expectations.

Transportation and Mobility Support

Even when on-site visits are unavoidable, transportation support can make participation feasible. This may include ride-share vouchers, dedicated shuttle services, or reimbursement for mileage and parking. Sites should also ensure physical accessibility—ramps, elevators, and seating areas for those with mobility issues. Appointment scheduling should avoid early mornings when older adults may face stiffness or slower mobility.

In one oncology study, offering transportation reimbursement and flexible scheduling increased elderly enrollment by 25% without extending recruitment timelines. Importantly, all such support must be clearly outlined in the informed consent form and approved by the IRB to avoid any perception of undue inducement.

Caregiver Engagement in Burden Reduction

Caregivers often play a central role in an elderly participant’s ability to attend visits, adhere to medication schedules, and complete study procedures. Trials can reduce burden by integrating caregiver support into the protocol—such as providing study summaries, flexible communication channels, and training on device use. In some cases, caregivers may even be allowed to perform basic assessments (e.g., weight checks, ePRO entries) if appropriately trained and documented.

Caregiver support aligns with ethical principles of respect and beneficence, ensuring the participant’s safety while reducing dropout risk. Studies show that caregiver engagement improves adherence rates and reduces protocol deviations in elderly cohorts by up to 30%.

Regulatory Considerations and Documentation

Any burden-reduction strategy must be fully documented in the protocol, approved by ethics committees, and included in the Trial Master File (TMF). Modifications to visit schedules, consent processes, or sample collection methods should be supported by risk assessments showing no compromise to participant safety or data integrity. SOPs should define procedures for remote assessments, device calibration, and data privacy. For detailed SOP templates, PharmaSOP.in offers industry-compliant frameworks.

Monitoring plans should address how remote data will be verified, and site staff should be trained to manage hybrid visit schedules. Regulators will expect evidence that decentralization does not impair adverse event reporting timelines or safety follow-up.

Case Study: Burden Reduction in a Geriatric Diabetes Trial

In a 24-month Phase III diabetes trial enrolling participants over 70, the sponsor implemented a hybrid model with quarterly in-person visits and monthly telehealth check-ins. Home nursing staff performed HbA1c sampling, with results uploaded directly to the EDC. The method maintained assay LOD and LOQ parameters identical to site collections, and all batches met MACO ≤0.1%. Participant retention at 12 months was 92%, compared to 78% in a previous fully site-based study.

Caregivers were given secure portal access to review visit schedules and lab results, which improved medication adherence and reduced missed visits. A PDE (permitted daily exposure) assessment was conducted for excipients in the trial drug, addressing tolerability concerns for participants with polypharmacy.

Conclusion: Making Trials Feasible for the Elderly

Reducing trial burden for elderly participants requires an integrated approach—combining decentralized visits, visit consolidation, mobility support, and caregiver engagement. Regulatory compliance remains non-negotiable, but flexibility in execution can greatly improve recruitment and retention. By addressing the specific needs of older adults, trials can produce more generalizable results while respecting the dignity and limitations of their participants.